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Bactericidal effect against non-dividing bacteria is a very advantageous,
but rare characteristic among antimicrobial agents, mostly possessed by those
affecting the cell membrane. These kinds of agents can kill bacterial cells without
lysis. We assessed these characteristics on primycin, a topical anti-staphylococcal
agent highly effective against prevalent multiresistant strains, as it also acts on the
cell membrane. In time-kill studies, primycin preserved its bactericidal activity
against growth-arrested Staphylococcus aureus cultures. The bactericidal action
was slower against growth-arrested cultures compared to the exponentially
growing ones to different extents depending on the manner of arrest. The
bactericidal effect was less inﬂuenced by stringent response and by protein
synthesis inhibition, proving that it does not depend on metabolic activity. In
contrast, uncoupling of the membrane potential predominantly slowed, and low
temperature almost stopped killing of bacteria. In consideration of published data,
these facts suggest that the antibacterial action of primycin involves disrupting of
the membrane potential, and is predominantly inﬂuenced by the membrane ﬂuidity.
Optical density measurements and transmission electron microscopy veriﬁed that
primycin kills bacterial cells without lysis. These results reveal favorable char-
acteristics of primycin and point to, and broaden the knowledge on its membrane-
targeted effect.
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Introduction
Most bactericidal antibiotics act only on dividing bacteria as the mechan-
isms of action thereof usually rely on interference with active metabolic pathways.
In antimicrobial chemotherapy, this phenomenon leads to persistence of non-
dividing, dormant bacteria in infection sites, evoking the necessity of prolonged
therapy, which promotes development of resistance [1]. For this reason, killing
activity of an antibiotic also on non-dividing bacteria is beneﬁcial to total clearing
of the infected area, especially in immunocompromised hosts. It is assumed that
antimicrobials acting on the bacterial cytoplasmic membrane usually bear this
advantage [1–3]. This kind of bactericidal action is capable of causing cell death
without lysis, leaving the bacterial cell wall – thus the physical integrity of the
bacterial cell – intact [4].
Primycin, a unique topical antibiotic discovered in the 1950s [5], was a good
candidate for these characteristics, as it belongs to those rare agents exerting their
bactericidal effect on the cytoplasmic membrane [6]. This antibiotic, bearing
antibacterial [5–7] and moderate antifungal activity [8, 9], is marketed as the active
substance of Ebrimycin® gel, a topical anti-infective medicinal product applied in
dermatology. Our recent study revealed that this long-neglected antibiotic
possesses with high and extended efﬁcacy against current multiresistant
Gram-positive bacteria including methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin-intermediate S. aureus, mupirocin-resistant S. aureus, and
vancomycin-resistant enterococci, in a concentration-dependent bactericidal
manner [7]. Moreover, these favorable features are backed up with very low
potential to trigger resistance development [7]. For these reasons, it is now a
subject of pharmaceutical developments addressing broader therapeutic ﬁelds,
including nasal MRSA decolonization.
Neither the effect of primycin against non-dividing bacteria nor its potential
bacteriolytic activity has yet been studied. We addressed these topics for their high
practical importance, and for gaining further information on the mechanism of the
bactericidal action of this drug.
Materials and Methods
Antimicrobial agents
Besides testing primycin (PannonPharma Ltd., Hungary), vancomycin
(Sigma-Aldrich, Budapest, Hungary) was used as a comparative agent, both
possessing with a well-characterized bactericidal effect on staphylococci.
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Mupirocin (Sigma-Aldrich), erythromycin (Sigma-Aldrich), and carbonyl
cyanide m-chlorophenyl hydrazone (CCCP) (Sigma-Aldrich) were used to
achieve growth arrests by different mechanisms in the model organism.
Antimicrobials were stored, handled, and dissolved according to the instruc-
tions of the manufacturers.
Bacterial strain
S. aureus ATCC 29213 was used as model organism in all the experiments.
Minimal inhibitory (MIC) and minimal bactericidal concentrations (MBC) of
primycin and vancomycin against this strain were determined by standard methods
of CLSI in our previous study [7]. The MIC/MBC values were 0.06/0.5 μg/ml and
1/1 μg/ml regarding primycin and vancomycin, respectively.
Time-kill studies and growth arrest conditions
Time-kill assays were performed by methods based on the CLSI standard [10].
Mueller–Hinton broth was used in 10 ml ﬁnal volumes. Antibiotics were applied in
concentrations multiples of their MBC values and parallel cultures without the agents
served as controls. Inoculum suspensions were made in sterile 0.9% w/v saline
solution from overnight plate cultures by adjustment to the 0.5 McFarland turbidity
standard. The initial inoculum concentration was aimed to be ∼106 cells/ml. The
reaction tubes were incubated for 24 h at 37 °C in ambient air. Serial tenfold dilutions
of 0.1 ml samples taken at 0, 1, 2, 4, 8, 12, and 24 h were made in sterile 0.9% w/v
saline solution, and 0.01 ml aliquots of these suspensions and also undiluted samples
were cultured in duplicates on Mueller–Hinton agar plates. Colonies were counted
after 24 h incubation in ambient air at 37 °C, and the number of colony forming units
(CFU) per ml was calculated. Limit of detection was 1.7 log10.
Besides control experiments made without any growth arrest, we
(a) modeled the nutrient starvation and the stringent response by adding mupirocin
in the bacteriostatic 0.25 μg/ml concentration [3], assessed the effect of (b) protein
synthesis inhibition due to erythromycin (8 μg/ml) [2], (c) membrane potential
impairment induced with the proton ionophore CCCP (10 μM) [2], and (d) growth
inhibition resulting from ice-bath incubation [2].
Assessment of the effect of primycin on culture cell density
Time-kill experiments were performed as described above but with an
elevated starter inoculum size equal to 0.1 OD600. The OD600 values of the cultures
were measured concurrently with the sample removals for CFU measurements.
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Transmission electron microscopy (TEM)
Primycin-treated (1 μg/ml) and vehicle control cultures with a starting
density of OD600= 0.1 were made in 10 ml Mueller–Hinton broth, and incubated
for 1 h at 37 °C in ambient air. In order to prepare cells for TEM analysis, the
cultures were centrifuged (1 min, 13,000 rpm) and resuspended in 20 μl
phosphate-buffered saline (PBS) solution. This suspension was dropped on a
microscope slide, and mixed with melted 5% agar solution. After 1 min solidiﬁ-
cation, small cubes (2 mm3) were cut, and these embedded cells were ﬁxed with
2.5% v/v glutaraldehyde in a 1.5 ml reagent tube at 4 °C overnight. After washing
(PBS, 3 × 10 min) the samples were postﬁxed in 1% w/v osmium tetroxide (1 h,
4 °C), and dehydrated in consecutive ethanolic steps (10 min each in 50, 70, 90,
96% v/v and abs. ethanol). Dehydration was completed with propylene oxide
(2 × 4 min). For embedding, the cubes ﬁrst were inﬁltrated with the mixture of
durcupan and propylene oxide (1:1) for 30 min, and then in pure durcupan
overnight at room temperature. Encapsulated samples were polymerized on 56 °C
for 48 h, thin sectioned (700 nm), and visualized under light microscope after
staining with toluidine blue (1%). For further analysis, embedded samples were
ultrathin sectioned (50 nm) with a LEICA Ultracut microtome, and stained by
saturated uranyl acetate (20 min) and lead citrate (3 min). Sections were placed on
grids and TEM was performed using a JEOL JEM-1200EX II microscope under
standard operating conditions at 54 kV.
Results
We assessed the effect of primycin on non-dividing S. aureus cells by the
time-kill method. Different growth arrest methods were applied to outline the
mechanism or the target structures of this action. In the time-kill assays, primycin
was applied in two concentrations, 2 × and 4 ×MBC, as it possesses with
concentration-dependent bactericidal effect. Vancomycin was applied in only a
single concentration (4 ×MBC) as its bactericidal effect is time-dependent. Tubes
ran with vancomycin served also as negative controls of cell division as it affects
only dividing cells.
In the control experiments, the bactericidal effect of both primycin and
vancomycin was apparent (Figure 1A). Primycin elicited 3 log10 decrease of CFU
in 1 h and 2 h, respectively, when applied in 4 × and 2 ×MBC. In case of
vancomycin treatment, the CFU count decreased by >3 log10 in 24 h.
When applying mupirocin treatment, primycin preserved its bactericidal
effect, though, the >3 log10 decrease in CFU was reached by only 2 h and
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12 h regarding 4 × and 2 ×MBC, respectively (Figure 1B). Killing curves of
primycin showed very similar graphs in case of arrested protein synthesis due to
erythromycin reaching the >3 log10 CFU decrease by 2 h and 24 h regarding
4 × and 2 ×MBC, respectively (Figure 1C). Primycin also preserved its killing
activity in cultures arrested by CCCP, however, only the 4 ×MBC could cause a
>3 log10 decrease in CFU by 12 h (Figure 1D). Inhibition of the growth by cold
temperature also inhibited the bactericidal effect of primycin (Figure 1E). Even if
applied in 4 ×MBC concentration, the CFU decrease did not reach even 1 log10.
Though the effect was minimal, we assumed that it was not completely abolished
as in case of vancomycin, but rather extremely slowed. When repeating the
experiment applying substantially higher concentration (16 ×MBC), killing effect
of primycin was apparent, however, reaching still only a 2 log10 decrease in CFU
by 24 h (Figure 1F).
Curves for vancomycin-treated cultures were practically identical with those
of the growth controls in all kinds of growth arrest, even when applied in a
concentration as high as 32 ×MBC (Figure 1F) to test elevated drug levels in cold
cultures. These results show that bacteriostasis rendered vancomycin ineffective as
anticipated.
We assessed the possible bacteriolytic effect of primycin by parallel
photometrical measurements of the reaction tubes at the sampling time points
of time-kill experiments conducted with a dense starting culture (OD600= 0.1).
Primycin was applied in 0.5 and 1 μg/ml concentrations.
As it can be seen in Figure 2, the CFU counts dropped in a concentration-
dependent manner, while the respective optical densities practically remained
evenly unchanged. This shows that primycin killed bacterial cells without lysis.
Figure 2. Primycin-induced changes in viability (CFU/ml) and optical density (OD600) of
exponentially growing S. aureus ATCC 29213 cultures expressed as the percentage of the values
at 0 h. Symbols: ▵ and ▿, CFU/ml and OD600 by 0.5 μg/ml primycin; ▴ and ▾, CFU/ml and OD600
by 1 μg/ml primycin, respectively
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Furthermore, TEM images were taken to visualize primycin-treated
(1 h, 1 μg/ml) and control bacterial cells (Figure 3).
No signs of lysis could be found in the samples of primycin-treated culture.
Dividing cells containing septa were sporadic, contrary to the control culture. Cells
in control samples appeared with well-deﬁned cell walls and membranes, and the
heterogeneous electron-density of the nucleoid regions were also visible. Treated
cells preserved their shape and integrity, but their internal contents became
Figure 3. Typical TEM images of control (A and B) and primycin-treated (1 μg/ml, 1 h) (C and D)
S. aureusATCC 29213. Scale bars: A, C: 0.2 μm; B, D: 1 μm. No signs of cell lysis are visible. Local
and diffuse white inﬁltrations (black arrows) under the cell wall of treated cells (C) are signs of
damage in the cell membrane
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homogeneously electron-dense, and discontinuities of the cytoplasmic membrane
pointed to its damage (Figure 3C).
Discussion
In the present study, we assessed the bactericidal effect of primycin on a
S. aureus reference strain under different growth arrest conditions. As none of
these could prevent primycin from killing bacteria it obviously does not require
cell division for its action.
Stringent response due to nutrient starvation – modeled by mupirocin
treatment – renders bacterial cells in a state of dormancy, resulting signiﬁcant
downregulation of many metabolic pathways, thus preventing many antibiotics
from killing the affected bacteria [11]. The fact that stringent response could
not prevent bactericidal action of primycin shows that it does not rely on
interaction with ongoing metabolic processes. Accordingly, inhibition of the
protein synthesis by erythromycin could not abolish bactericidal activity of
primycin either.
On the other hand, growth arrest methods substantially affecting the
cytoplasmic membrane also predominantly modiﬁed the killing rate by
primycin. Protective effect of CCCP pretreatment against bactericidal activity
is known in case of cationic antimicrobial peptides [12]. This phenomenon is
associated with the membrane potential disrupting effect of these agents, against
which the microbe exerts adaptive responses triggered by the membrane
potential uncoupling due to CCCP [12]. Though further studies are needed to
conﬁrm if this mechanism applies also for the decreased killing rate of primycin
by CCCP treatment, it seems to be a plausible explanation as primycin is known
to increase ion permeability and conductivity of the bacterial cytoplasmic
membrane [5].
The most prominent drop in killing rate of primycin occurred in cold
cultures. Besides reducing enzymatic activity, low temperature causes drastic
decrease of membrane ﬂuidity [13]. As this latter effect means a fundamental
difference compared to the physiologic consequences of growth arrest by
mupirocin, probably it is the main cause of the major activity reduction of
primycin in cold cultures. This assumption is consistent with published data.
Lower membrane ﬂuidity has been observed to entail decreased primycin
susceptibility of an ergosterol-less Candida albicans mutant strain possessing
a more compact cell membrane compared to the wild type [14, 15]. Presumably,
the low membrane ﬂuidity and the decreased diffusion rate due to low tempera-
ture hindered the integration of primycin into the cell membrane, which is
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necessary to exert its effect [9, 15]. This can also explain the more rapid killing
of exponentially growing bacteria by primycin compared to that of any growth-
arrested cultures, as the membrane ﬂuidity is known to be increased during the
logarithmic phase [16]. These ﬁndings indicate the need for further investiga-
tions to clarify the connections between membrane ﬂuidity/rigidity and the
antibacterial effect of primycin.
Our results show that primycin kills bacterial cells without cell lysis, which
is also coherent with the assumption of a membrane-targeted effect [4]. This
theory was further supported by the TEM images where damaged cell membrane
could be observed beside an intact cell wall. Further, detailed investigations are
needed to outline the mechanisms evoking the apparent changes in the ultrastruc-
ture, especially regarding the cytoplasmic membrane and the cytoplasm.
Based on the investigations reported here, the bactericidal action of primycin
does not require cell division, is not due to interaction with ongoing metabolic
pathways, and is exerted without cell lysis. The results support the knowledge
of membrane-targeted effect of primycin, while providing further details. The
suggested membrane potential disrupting effect and the inﬂuence of membrane
ﬂuidity/rigidity on the action are worth for further investigations. From the practical
point of view, our results revealed very favorable characteristics of this antibiotic
promising rapid and total clearance of infected or colonized sites on application [17].
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